My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

BioNTech SE - American Depositary Shares (NQ:BNTX)

105.87 +0.11 (+0.10%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

61 62 Next >

Exxon Mobil To $120? Here Are 10 Top Analyst Forecasts For Tuesday ↗

September 24, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 23, 2024

Via Benzinga

Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? ↗

September 22, 2024

10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90%

Via Benzinga

How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery ↗

September 17, 2024

BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days.

Via Investor's Business Daily

Forecasting The Future: 8 Analyst Projections For BioNTech ↗

September 13, 2024

Via Benzinga

Market Whales and Their Recent Bets on BNTX Options ↗

September 13, 2024

Via Benzinga

Unveiling 12 Analyst Insights On BioNTech ↗

August 19, 2024

Via Benzinga

Here's Why Everyone's Talking About Summit Therapeutics ↗

September 17, 2024

Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.

Via The Motley Fool

DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions ↗

September 16, 2024

Florida advises against mRNA Covid vaccines for vulnerable residents, citing safety concerns. Gov. DeSantis' administration urges healthcare providers to prioritize alternative vaccines for seniors and...

Via Benzinga

Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio? ↗

September 15, 2024

These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also raised price targets for Applovin and Arm Holdings.

Via Benzinga

Should You Buy Novavax Stock After This Regulatory Win? ↗

September 13, 2024

The biotech continues to earn important wins, but is it enough?

Via The Motley Fool

GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech ↗

September 11, 2024

GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clinical trials. Moderna and Pfizer's partner BioNTech are still developing HSV...

Via Benzinga

Why Is Moderna Stock Trading Higher On Monday? ↗

September 09, 2024

Moderna's Laval, Quebec, facility received a Drug Establishment License from Health Canada, allowing it to produce mRNA vaccines domestically by 2025. The site will manufacture COVID-19, RSV, and flu...

Via Benzinga

Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows ↗

September 06, 2024

Moderna is conducting a Phase 1/2 trial of mRNA-1769, a potential mpox vaccine for adults. Early research shows it may outperform Bavarian Nordic's Jynneos in reducing severe disease in monkeys.

Via Benzinga

UK, Taiwan Approve Moderna's Updated COVID-19 Shot ↗

September 03, 2024

The Medicines and Healthcare Products Regulatory Agency has approved Moderna's updated COVID-19 vaccine targeting the JN.1 variant, available for eligible groups through the NHS autumn program and for...

Via Benzinga

Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million ↗

August 31, 2024

UCB announced plans to divest its current China five-drug portfolio, narrowing its China focus to commercialize soon-to-arrive late-stage clinical assets. It will sell this “mature” neurology and...

Via Talk Markets

Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales ↗

August 29, 2024

BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these innovative treatments face challenges in cost, scalability, and...

Via Benzinga

Americans To Access COVID-19 Test Kits For Free As US Government Restarts Free At-Home Program ↗

August 26, 2024

US households can order free COVID-19 tests starting in late September as the government reopens the program ahead of the fall virus season.

Via Benzinga

FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot ↗

August 22, 2024

The FDA granted emergency use authorization for updated mRNA COVID-19 vaccines targeting the Omicron KP.2 strain, including new formulas from Moderna and Pfizer/BioNTech. These vaccines, designed to...

Via Benzinga

FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch ↗

August 19, 2024

The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak.

Via Benzinga

Topics ETFs

FDA Allows Resumption Of BioNTech/MediLink Therapeutics Partnered Phase 1 Study For Cancer Drug With Lower Dose ↗

August 19, 2024

FDA lifts partial hold on MediLink Therapeutics' phase 1 trial for HER3-targeting ADC BNT326/YL202 in advanced lung and breast cancer patients; trial resumes with revised dose limits following safety...

Via Benzinga

Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell? ↗

August 19, 2024

A clinical-trial failure for Pfizer and BioNTech means Moderna is leading the race to develop a combo shot for the flu and COVID-19.

Via The Motley Fool

Why Pfizer Stock Slumped on Friday ↗

August 16, 2024

Investors were cautiously pessimistic about the latest news coming out of the company's lab.

Via The Motley Fool

Pfizer Slides Toward Sell Zone After BioNTech-Tied Covid/Flu Shot Misses Its Mark ↗

August 16, 2024

The company is now considering whether it needs to change up the vaccine to pass muster.

Via Investor's Business Daily

Pfizer, BioNTech's COVID-19/Flu Combo Vaccine Fails To Meet Key Goal In Late-Stage Study ↗

August 16, 2024

Pfizer and BioNTech report Phase 3 results for their combined mRNA vaccine against influenza and COVID-19. The trial met one of two primary immunogenicity objectives. Adjustments are planned to improve...

Via Benzinga

Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows ↗

August 13, 2024

COVID-19 vaccinations could lower the incidence of heart attacks and strokes, according to a new study by UK universities. The research shows a significant reduction in cardiovascular events among...

Via Benzinga

Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows ↗

August 13, 2024

A recent NIH study reveals no clear diagnostic test for Long Covid, highlighting ongoing challenges in identifying and treating the condition affecting millions of Americans. Researchers continue to...

Via Benzinga

3 Biotech Stocks With Promising Drug Pipelines: August 2024 ↗

August 08, 2024

The biotech stocks with promising pipelines could see shares soar if drugs in late-stage trials get FDA approval.

Via InvestorPlace

This Cognizant Technology Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday ↗

August 07, 2024

Via Benzinga

BioNTech Se (BNTX) Q2 2024 Earnings Call Transcript ↗

August 05, 2024

BNTX earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 9

...

61 62 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.